Breast SurgeryMedicine and Medical Science

For Japanese females, the incidence of breast cancer is the highest amongst all cancers. The incidence and mortality rate of breast cancer are rising every year. In our research group, studies ranging from molecular biological research to clinical trials are performed with the aim of generating new diagnostic, therapeutic and preventive tools. Furthermore, studies of the treatment personalization according to an individual’s risk profile are being initiated to create a next generation breast cancer medical platform.

Lab Website

Research and Education

In order to realize the personalized medicine in breast cancer treatment, genomic, epigenetic and transcriptomic profiles of breast cancer are being analyzed. Furthermore, host reactions to breast cancers, including immune and inflammatory responses, are investigated using biomaterials from breast cancer patients. Therefore, a variety of translational researches as well as biomarker development are activated in this laboratory.
Currently, several types of new diagnostic technologies are under development in our laboratory, including photo-acoustic technologies for imaging of tumor vasculature and its function, imaging mass spectrometry technologies to identify next generation biomarkers for early detection of breast cancer, and microRNA profiling system and algorithm to predict treatment response of breast cancer. In parallel, studies to create a new approach for the prevention of breast cancer are being initiated according to a concept of life cycle care of life style.
Many innovative investigators are engaged in creating new ideas for understanding of breast cancer and the development of novel preventive, diagnostic and therapeutic tools for breast cancer patients.

Recent Publications

    1. Takada M, Yoshimura M, Kotake T, Kawaguchi K, Uozumi R, Kataoka M, Kato H, Yoshibayashi H, Suwa H, Tsuji W, Yamashiro H, Suzuki E, Torii M, Yamada Y, Kataoka T, Ishiguro H, Morita S, Toi M. Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. Sci Rep. 2022;12:22397
    2. Kawaguchi K, Maeshima Y, Toi M. Tumor immune microenvironment and systemic response in breast cancer. Med Oncol. 2022, 29;39:208.
    3. Ravi Velaga, Sunao Tanaka, Masakazu Toi. Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours.Cancer Drug Resist. 2022; 5(2): 487–497.
    4. Nakayama Y, Hanada M, Koda H, Sugimoto M, Takada M, Toi M. Breast cancer detection using volatile compound profiles in exhaled breath via selected ion-flow tube mass spectrometry. J Breath Res. 2022;17. doi: 10.1088/1752-7163/aca696.
    5. Chenfeng He, Riyo Konishi, Ayano Harata,Yuki Nakamura,Rin Mizuno, Mayuko Yoda, Masakazu Toi, Kosuke Kawaguchi, Shinpei Kawaoka Serum amyloid alpha 1-2 are not required for liver inflammation in the 4T1 murine breast cancer model.Front Immunol. 2023; 14: 1097788.

Laboratory

Associate professor： Masahiro Takada
Assistant Professor： Masahiro Kawashima, Kosuke Kawaguchi, Ayane Yamaguchi
Program-Specific Assistant Professor： Hanako Shimizu

TEL：+81-75-751-3660
FAX：+81-75-751-3616
E-mail： nyusen@kuhp.kyoto-u.ac.jp
URL： http://www.brca.jp/

Research Fields
  1. Home
  2. Research
  3. Research Fields